https://medicine.ouhsc.edu/academic-departments Parent Page: Academic Departments id: 27839 Active Page: Detailsid:27860

Faculty

Dr. Surendra Shukla, PhD
Oncology Science

Surendra Shukla, PhD

Assistant Professor


940 Stanton L. Young Blvd., Oklahoma City, OK  73104

 

405.271.8001 Ext. 52238

Surendra-Shukla@ouhsc.edu


Education:

Ph.D., International Centre for Genetic Engineering and Biotechnology, New Delhi, India

Post-doctoral Fellowship, UNMC, Omaha, NE, USA


Clinical/Research Interests:

Research Interests

Our research interests are mainly focused on:

  • Exploring the molecular mechanism of therapeutic resistance in gastrointestinal cancers with specific focus on pancreatic cancer and liver cancer.
  • Designing novel therapeutic strategy to over-come therapy resistance in different types of cancers.
  • To understand molecular and metabolic basis of cancer-associated cachexia.

The key objective of my laboratory is to gain insight about the metabolic and epigenetic crosstalk in development of therapy resistance and cancer associated systemic syndromes (CASS) such as cachexia. We utilize different in vitro as well as in vivo model systems along with metabolomics, transcriptomics and genetics tools to perform the cutting-edge research in focused areas. Our ultimate goal is to find novel therapeutic interventions targeting metabolic and epigenetic aberrations of cancer and, utilize them to improve the current standard of care therapies.


Select Publications:

King RJ, Shukla SK, He C, Vernucci E, Thakur R, Attri KS, Dasgupta A, Chaika NV, Mulder SE, Abrego J, Murthy D, Gunda V, Pacheco CG, Grandgenett PM, Lazenby AJ, Hollingsworth MA, Yu F, Mehla K, Singh PK. CD73 induces GM-CSF/MDSC-mediated suppression of T cells to accelerate pancreatic cancer pathogenesis. Oncogene. 2022 Jan 10. doi: 10.1038/s41388-021-02132-6.

Hu T, Shukla SK, Vernucci E, He C, Wang D, King RJ, Jha K, Siddhanta K, Mullen NJ, Attri KS, Murthy D, Chaika NV, Thakur R, Mulder SE, Pacheco CG, Fu X, High RR, Yu F, Lazenby A, Steegborn C, Lan P, Mehla K, Rotili D, Chaudhary S, Valente S, Tafani M, Mai A, Auwerx J, Verdin E,Tuveson D, SinghPK. Metabolic Rewiring by Loss of Sirt5 Promotes Kras-induced Pancreatic Cancer Progression. Gastroenterology. 2021 Jul 7:S0016-5085(21)03159-0. doi: 10.1053/j.gastro.2021.06.045.

Shukla SK, Markov SD, Attri KS, Vernucci E, King RJ, Dasgupta A, Grandgenett PM, Hollingsworth MA, Singh PK, Yu F, Mehla K. Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia. Cancer Lett. 2020 Aug 1;484:29-39.

Dasgupta A, Shukla SK, Vernucci E, King RJ, Abrego J, Mulder SE, Mullen NJ, Graves G, Buettner K, Thakur R, Murthy D, Attri KS, Wang D, Chaika NV, Pacheco CG, Rai I, Engle DD, Grandgenett PM, Punsoni M, Reames BN, Teoh-Fitzgerald M, Oberley-Deegan R, Yu F, Klute KA, Hollingsworth MA, Zimmerman MC, Mehla K, Sadoshima J, Tuveson DA, Singh PK. SIRT1-NOX4 signalling axis regulates cancer cachexia. J Exp Med. 2020 Jul 6;217(7):e20190745.

Shukla SK, Dasgupta A, Mulder SE, Singh PK. Molecular and Physiological Evaluation of Pancreatic Cancer-Induced Cachexia. Methods Mol Biol. 2019; 1882: 321-333.

Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, King RJ, Abrego J, Goode GD, Dasgupta A, Illies AL, Gebregiworgis T, Dai B, Augustine JJ, Murthy D, Attri KS, Mashadova O, Grandgenett PM, Powers R, Ly QP, Lazenby AJ, Grem JL, Yu F, Matés JM, Asara JM, Kim JW, Hankins JH, Weekes C, Hollingsworth MA, Sarkova NJ, Sasson AR, Fleming JB, Oliveto JM, Lyssiotis CA, Cantley LC, Berim L, Singh PK. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell. 2017 Jul 10;32(1):71-87.

Tadros S, Shukla SK, King RJ, Gunda V, Vernucci E, Abrego J, Chaika NV, Yu F, Lazenby AJ, Berim L, Grem J, Sasson AR, Singh PK. De Novo Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer. Cancer Res. 2017 Oct 15;77(20):5503-5517

Rajput P, Shukla SK, Kumar V. The HBx oncoprotein of hepatitis B virus potentiates cell transformation by inducing c-Myc-dependent expression of the RNA polymerase I transcription factor UBF. Virol J. 2015 Apr 14;12:62.

Shukla SK, Gebregiworgis T, Purohit V, Chaika NV, Gunda V, Radhakrishnan P, Mehla K, Pipinos II, Powers R, Yu F, Singh PK. Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Cancer Metab. 2014 Sep 1; 2:18. doi: 10.1186/2049-3002-2-18.

Shukla SK, Kumar V. Hepatitis B virus X protein and c-Myc cooperate in the upregulation of ribosome biogenesis and in cellular transformation. FEBS J. 2012 Oct; 279(20):3859-71.

Complete List of Published Work in MyBibliography:

https://pubmed.ncbi.nlm.nih.gov/?term=Surendra+Shukla&sort=date&size=100